In conclusion, we have successfully identified several novel antigens of K. pneumoniae and identified three proteins potentially harboring linear epitopes. Bumetanide Subsequently, we achieved to identify two sequences displaying specificity during experimental investigations; however, one of these is doubtful as homology analysis has revealed it to be highly conserved among a broad spectrum of bacterial species. Still, GAVVALSTTFA of KPN_00363 was identified to be specific both experimentally and has shown four residues within the eleven amino acid sequence to occur predominantly in K. pneumoniae only. Thus, the likelihood for this linear epitope to be specific is high. This assumption was confirmed by alanine scanning revealing a number of pivotal residues for antibody binding. Moreover, it was unearthed that neither E. coli nor S. enterica antibodies were able to bind to any of the sequences, original and modified. Benzocaine Subsequent investigations might help to further nurture the insight into the suitability of this peptide for diagnostic and therapeutic applications. Thus, monoclonal antibodies ought to be devised to be used for affinity investigations via BIAcore and to determine kinetics. Furthermore, monoclonal antibodies could be used within a potential diagnostic tool and after validation ought to be tested with whole bacteria. If these antibodies are able to specifically detect intact K. pneumoniae cells, the resulting antibody might well be suited for integration into a point-of-care device. In a different approach, the identified epitope sequence could easily be produced in large quantity. This peptide might serve some role in serological screenings, especially if it proves to be immunodominant. Consequently, antibodies against this epitope might be present in a plethora of patient sera. Finally, all proteins identified here might be suitable candidates for vaccine development independent of the existence of a linear epitope, as structural epitopes might well be present and antigenicity ensured. Nevertheless, additional in-depth analysis is required to determine a number of the key aspects of vaccine development prior to use.